Value of Health Part III: Potential Disruptors' Impact to Value, Access & Reimbursement

December 10, 2019 4:00 PM - 6:00 PM

MassBio, 300 Technology Square 8th Fl, Cambridge, MA 02139

Register Now!

This event, Part III in a three part series that will explore the value of health, will consider disruptions to the ever-evolving value, access & reimbursement landscape as new players enter the arena and others consolidate. What impact will mergers between payers and PBMs have on drug pricing, patient access, and the ability to track and analyze data? How are digital technologies changing the way we track patients and ensure access? What impact will one-time cures have on the system? What new financing methodologies are gaining traction and what else can we do to support their widespread adoption?  What new players are disrupting the value equation? We'll attempt to answer those questions and more, with MassBio's Bob Coughlin as the moderator.

We believe this issue is especially timely. We’re at an inflection point, with science that’s been tested for decades finally becoming a reality for patients and a payer system that has not caught up with this level of innovation. Myriad factors are combining to alter the status quo – with policymakers demanding action, and healthcare stakeholders agreeing that we must come up with real solutions. If we don’t come together and address the value equation as an industry and ensure patient access to all new therapies, government or other stakeholders will – and they will likely get it wrong. 

Drinks and appetizers will be provided. If you're not a MassBio member but are interested in attending, please email contact us at communications@massbio.org.

Executive Director, CMS Policy and Reimbursement at Novartis
Vadim Lubarsky is a 20-year veteran of healthcare policy, having served in numerous executive and analytical positions both in the private and public sectors. Currently, Vadim is the Executive Director for Centers for Medicare and Medicaid Services (CMS) Policy and Reimbursement at Novartis. In this capacity, he leads engagement with CMS, and other Health and Human Services (HHS) stakeholders, to positively impact policy issues of importance to Novartis. Vadim works collaboratively across CMS to oversee direct engagement in resolving a range of policy issues related to reimbursement, access and policy. Previously, Vadim served in a similar role as the Director for HHS within the Federal Government Relations Group at GlaxoSmithKline (GSK). Vadim has worked with HHS to achieve favorable payment and coverage decisions for various GSK products, to develop and impact key regulations, and on the implementation of the Affordable Care Act (ACA) provisions specific to the GSK portfolio. Vadim also led the Medicare and Medicaid practice for a mid-sized healthcare focused financial services firm, where he advised private equity and venture capital on the regulatory and legislative healthcare environment, specifically focusing on federal reimbursement policy. Prior to the private sector, Vadim spent over 11 years with CMS. During his time with the Agency, Vadim served as a special assistant to the Administrator, an Advisor in the CMS Coverage and Analysis Group, and an analyst in both the Center for Beneficiary Services and in the Program Integrity Group. Vadim received both an MBA in health care management and Bachelor of Arts degree from Loyola College in Maryland, graduating summa cum laude. He currently resides in Annapolis, MD with his wife and two daughters.